Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: GSH-responsive degradable nanodrug for glucose metabolism intervention and induction of ferroptosis to enhance magnetothermal anti-tumor therapy

Fig. 2

A Release profiles of LND from LFMP with or without GSH. B The change of GSH level of Fe3O4, FM, and LFMP in PBS solution ([GSH] = 5 mM) during 72 h. C The ability of FMP to consume GSH ([GSH] = 5 mM) under different concentration conditions. D Quantitative temperature curve of LFMP in vitro. E Heating curves of the LFMP (0.4 mg/mL) exposed to the AMF (17.5 kA/m, 250 kHz) for five on/off cycles. F Corresponding average dynamic light scatterings (DLS) diameter of LFMP in GSH. G Viabilities of EMT-6 cells co-incubated with different concentrations of Fe3O4 for 24 h, 48 h, 72 h. H Viabilities of EMT-6 cells co-incubated with different concentrations of MP for 24 h, 48 h, 72 h. I Viabilities of EMT-6 cells co-incubated with different concentrations of LND for 24 h, 48 h, 72 h. Data are shown mean ± SD, n = 5. *p < 0.05, **p < 0.01, ***p < 0.005

Back to article page